Convatec commences share buyback programme
London, UK, 20 August 2025: Convatec announces a non-discretionary share buyback programme (the "Programme") to return up to $300 million of surplus capital to shareholders. This is in accordance with Convatec’s disciplined approach to capital allocation and previously stated policy. It follows confirmation of full year guidance with Convatec’s interim results, together with a refresh of cash flow needs for the second half of the year. The Programme will commence immediately and run up to 31 December 2025. The Programme may be extended by further notification.
Convatec has entered into an agreement with UBS AG London Branch (“UBS”) to conduct the Programme on its behalf and to make independent trading decisions within certain pre-set parameters.
Any Share purchases will be made in accordance with (i) the general authority of the Company to repurchase shares granted by shareholders at the Company’s Annual General Meeting held on 22 May 2025; (ii) the Market Abuse Regulation 596/2014 and the Commission Delegated Regulation (EU) 2016/1052 (both as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018); and (iii) Chapter 9 of the Financial Conduct Authority's UK Listing Rules. Up to 204,978,956 ordinary shares of 10 pence each in the Company (the “Shares”) may be acquired as part of the Programme for a maximum aggregate consideration of $300 million. There is no guarantee that the programme will be implemented in full. The purpose of the Programme is to reduce Convatec’s share capital. Shares acquired by UBS will be sold on to the Company and will, to the extent required to satisfy share awards under the Company's employee share plans, be held in treasury, and the remainder will be cancelled.
Media: MediaRelations@convatec.com
Investor Relations: IR@convatec.com
About Convatec
Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With more than 10,000 colleagues, we provide our products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention and protection of at-risk skin, to improved patient outcomes and reduced care costs. Convatec's revenues in 2024 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com
Press Release
20-Aug-25
Corporate
Convatec commences share buyback programme
Non-discretionary share buyback programme to return up to $300 million of surplus capital to shareholders
Read more Read more29-Jul-25
Corporate
Financial Performance
Interim results for the six months ended 30 June 2025
Delivering broad-based revenue growth, margin expansion & double-digit EPS growth
Read more Read more24-Jul-25
Corporate
Advanced Wound Care
Convatec secures US and European regulatory clearance for Aquacel™ ConvaFiber...
Read more Read more15-Jul-25
Corporate
Advanced Wound Care
Convatec responds to CMS draft payment proposal for skin substitutes in the U...
Convatec notes the draft payment proposal from the Centers for Medicare & Medicaid Services
Read more Read more01-Jul-25
Corporate
Continence Care
Ostomy Care
Comment on CMS proposed rule change issued 30 June 2025
Convatec notes the Centers for Medicare & Medicaid Services (CMS) proposed rule published on 30 June 2025
Read more Read more26-Jun-25
Corporate
Infusion Care
Convatec welcomes regulatory approval of subcutaneous apomorphine infusion f...
Convatec’s Neria™ Guard infusion set is used for continuous subcutaneous infusion of a wide range of pharmaceuticals ...
Read more Read more22-May-25
Corporate
Financial Performance
AGM trading update for the four months ended 30 April 2025
Strong start to the year, on track to deliver targets
Read more Read more20-May-25
Corporate
Infusion Care
Advancing subcutaneous infusion therapy for patients through innovation and p...
More than one million people around the world rely on Convatec infusion sets every day
Read more Read more25-Apr-25
Corporate
Advanced Wound Care
Convatec receives regulatory approval for ConvaNiox™
New solution set to improve patient outcomes for hard to heal wounds
Read more Read more11-Apr-25
Corporate
Advanced Wound Care
Convatec welcomes postponement of Local Coverage Determinations (LCDs) on ski...
Medicare patients in the US, supported by healthcare professionals (HCPs), will continue to benefit from InnovaMatrix®.
Read more Read more31-Mar-25
Corporate
Ostomy Care
Convatec announces exclusive collaboration with largest Wound, Ostomy and Con...
Unique global programme and collaboration with Wound, Ostomy, and Continence Nurses Society™ (WOCN®)
Read more Read more18-Mar-25
Corporate
Advanced Wound Care
Convatec showcases its strongest wound care innovation pipeline ever at EWMA
Convatec will highlight key findings and the latest developments designed to deliver better healing outcomes
Read more Read more